Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma

Published on 17 Feb 2025
Last Updated on 4 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, to be used according to the STRIDE regimen (single-dose tremelimumab in combination with regular-interval durvalumab) for treating unresectable hepatocellular carcinoma. Patients must not have received prior systemic therapy and must have adequate liver function as assessed by the Child-Pugh scoring system.

Funding status

Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.

Clinical indication, subsidy class and MediShield Life claim limits for durvalumab and tremelimumab are provided in the Annex.

Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma (Updated 4 Jun 2025) [PDF, 205 KB]

PES Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma (Updated 4 Jun 2025) [PDF, 59 KB]